Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 8/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073856 | 0.88 | RORC (0.42) | LMNACYP2C9TSHRBLMPPARA | |
| SCHEMBL671693 | 0.87 | GAA (0.43) | LMNACYP2C9TSHRBLMPPARA | |
| SCHEMBL10073858 | 0.75 | NR3C2 (0.48) | LMNAKMT2ASMN1; SMN2MEN1GAA | |
| SCHEMBL10073885 | 0.73 | CTSK (0.33) | KMT2AMEN1 | |
| SCHEMBL544862 | 0.72 | LMNA (0.36) | LMNACYP2C9TSHRBLMPPARA | |
| SCHEMBL15960825 | 0.71 | MAPT (0.43) | TSHRKMT2AMEN1HTT | |
| SCHEMBL11209553 | 0.71 | SMN1; SMN2 (0.50) | CYP2C9TSHRBLMSMN1; SMN2HTT | |
| SCHEMBL28612654 | 0.69 | KMT2A (0.37) | LMNATSHRKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL669757 | 0.69 | CTSK (0.34) | KMT2AMEN1 | |
| SCHEMBL668943 | 0.68 | CTSK (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046455-A1 | Catalytic Cyclopropanation of Alkenes with Alpha-Cyano-Diazoacetates | NATIONAL SCIENCE FOUNDATION | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046455-A1 | Catalytic Cyclopropanation of Alkenes with Alpha-Cyano-Diazoacetates | PPOX, POR, PCCA | LMNA 2060/4885CYP2C9 998/4885TSHR 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.